Christopher Stokoe

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer et al. · Journal of Clinical Oncology · 2019 · 420 citations · Full text

Medicine, Oncology, Pharmacology +17

Word sense disambiguation in information retrieval revisited

Christopher Stokoe, Michael Oakes, John Tait · 2003 · 193 citations

Computing, Computer Science, Computational Linguistics +13

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study

Stephen E. Jones, Rufus Collea, Devchand Paul et al. · The Lancet Oncology · 2013 · 135 citations

Medicine, Oncology, Pharmacology +14

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

Joyce O’Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao et al. · Clinical Cancer Research · 2015 · 63 citations

Medicine, Oncology, Pharmacotherapy +16

Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

L. Fehrenbacher, RS Cecchini, CE Geyer et al. · Cancer Research · 2018 · 50 citations

Medicine, Oncology, Pharmacology +13